Patents by Inventor David John Nash

David John Nash has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210101887
    Abstract: The invention relates to processes for preparing isoindolin-1-one derivatives, and in particular processes for preparing (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The invention also relates to crystalline forms of the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid and its salts.
    Type: Application
    Filed: March 28, 2018
    Publication date: April 8, 2021
    Applicants: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Steven HOWARD, Benjamin David CONS, Jeffrey David ST. DENIS, Charlotte Mary GRIFFITHS-JONES, Steven Douglas HISCOCK, Rhian Sara HOLVEY, Alan Richard BURNS, David COUSIN, Hannah Louise DEXTER, Guillaume François PARRA, John Paul WATTS, Robert JEWELL, Jennifer Ann STOCKWELL, Kim Louise HIRST, Isabelle Anne LEMASSON, David John NASH, James Daniel OSBORNE, Jonas Calleja PRIEDE, Nicholas Paul RICHARDS, Aaron Michael DUMAS, Brian Christopher BISHOP, David PARRY-JONES, Jeremy Peter SCOTT, Meenakshi Sundaram SHANMUGHAM, Peter Richard MULLENS, David Charles LATHBURY, Darren James DIXON, Matthew James GAUNT
  • Publication number: 20170324102
    Abstract: A fuel cell system comprises a fuel cell having an anode flow path extending through the fuel cell between an anode inlet and an anode outlet, and a cathode flow path extending through the fuel cell between a cathode inlet and a cathode outlet. An anode purge valve is coupled to the anode outlet and has an outlet coupled to the cathode inlet. A purge valve controller is configured to effect a purge cycle by opening and closing the anode purge valve and to monitor a fuel cell voltage profile during the purge cycle to determine an operational state of the anode purge valve. A fuel cell voltage drop during a period following a command signal instructing opening of the anode purge valve is used to indicate successful start of a purge cycle. A fuel cell voltage rise during a period following a command signal instructing closing of the anode purge valve is used to indicate a successful end to a purge cycle.
    Type: Application
    Filed: December 3, 2015
    Publication date: November 9, 2017
    Applicant: Intelligent Energy Limited
    Inventors: Gareth David John Nash, David Edgar, Emma Caroline Louise Burrow
  • Patent number: 8785628
    Abstract: A series of substituted [1,3,5]triazin-2-yl derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Grant
    Filed: March 2, 2010
    Date of Patent: July 22, 2014
    Assignee: UCB Pharma, S.A.
    Inventors: Daniel Rees Allen, Roland Bürli, Alan Findlay Haughan, Jonathan David MacDonald, Mizio Matteucci, David John Nash, Andrew Pate Owens, Gilles Raphy, Elizabeth Anne Saville-Stones, Andrew Sharpe
  • Publication number: 20120053167
    Abstract: A series of substituted [1,3,5]triazin-2-yl derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Application
    Filed: March 2, 2010
    Publication date: March 1, 2012
    Applicant: UCB PHARMA, S.A.
    Inventors: Daniel Rees Allen, Roland Bürli, Alan Findlay Haughan, Jonathan David MacDonald, Mizio Matteucci, David John Nash, Andrew Pate Owens, Gilles Raphy, Elizabeth Anne Saville-Stones, Andrew Sharpe
  • Publication number: 20120004273
    Abstract: Disclosed herein are compounds of formula (I) and: wherein: X is Ar—C(O)CH(R20)— or Ar1—NHC(O)CH2—; and Ar is: naphthyl optionally substituted with one or more groups Y; pyridyl optionally substituted with one or more groups Z; or the group Ar1 etc, these compounds being useful for treating neurological diseases such as schizophrenia, dementia or attention deficit disorder.
    Type: Application
    Filed: January 30, 2008
    Publication date: January 5, 2012
    Inventors: Nadia Mamoona Ahmad, Clive Leslie Branch, Albert Andrzej Jaxa-Chamiec, Justine Yeun Quai Lai, David John Nash
  • Patent number: 7928124
    Abstract: Disclosed are N-aroyl cyclic amine derivatives having the formula: where the variables are as define herein, and their use as pharmaceuticals, specifically as orexin receptor antagonists.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: April 19, 2011
    Assignee: SmithKline Beecham Limited
    Inventors: Clive Leslie Branch, Wai Ngor Chan, Amanda Johns, Christopher Norbert Johnson, David John Nash, Riccardo Novelli, Jean-Pierre Pilleux, Roderick Alan Porter, Rachel Elizabeth Anne Stead, Geoffrey Stemp
  • Patent number: 7928125
    Abstract: Disclosed are N-aroyl cyclic amine derivatives having the formula: where the variables are as define herein, and their use as pharmaceuticals, specifically as orexin receptor antagonists.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: April 19, 2011
    Assignee: SmithKline Beecham Limited
    Inventors: Clive Leslie Branch, Wai Ngor Chan, Amanda Johns, Christopher Norbert Johnson, David John Nash, Riccardo Novelli, Jean-Pierre Pilleux, Roderick Alan Porter, Rachel Elizabeth Anne Stead, Geoffrey Stemp
  • Patent number: 7897618
    Abstract: Disclosed are N-aroyl cyclic amine derivatives having the formula: where the variables are as define herein, and their use as pharmaceuticals, specifically as orexin receptor antagonists.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: March 1, 2011
    Assignee: SmithKline Beecham Limited
    Inventors: Clive Leslie Branch, Wai Ngor Chan, Amanda Johns, Christopher Norbert Johnson, David John Nash, Riccardo Novelli, Jean-Pierre Pilleux, Roderick Alan Porter, Rachel Elizabeth Anne Stead, Geoffrey Stemp
  • Patent number: 7893090
    Abstract: Disclosed are N-aroyl cyclic amine derivatives having the formula: where the variables are as define herein, and their use as pharmaceuticals, specifically as orexin receptor antagonists.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: February 22, 2011
    Assignee: SmithKline Beecham Limited
    Inventors: Clive Leslie Branch, Wai Ngor Chan, Amanda Johns, Christopher Norbert Johnson, David John Nash, Riccardo Novelli, Jean-Pierre Pilleux, Roderick Alan Porter, Rachel Elizabeth Anne Stead, Geoffrey Stemp
  • Publication number: 20100105713
    Abstract: Compounds of formula (I) or a salt thereof are provided: wherein R6, R7, R9, R10, R11, X, n, p, Ar and m are as defined in the description. Uses of the compounds as medicaments, and in the manufacture of medicament for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder are also disclosed. The invention further discloses pharmaceutical compositions and combinations comprising the compounds.
    Type: Application
    Filed: January 30, 2008
    Publication date: April 29, 2010
    Applicants: GLAXO GROUP LIMITED, UNIVERSITY OF NOTTINGHAM
    Inventors: Nadia Mamoona Ahmad, Daniele Andereotti, Justine Yeun Quai Lai, Howard Robert Marshall, David John Nash, Roderick Alan Porter
  • Publication number: 20100029700
    Abstract: Novel acetophenone compounds of formula (I), compositions containing (I), processes for the preparation of (I), and use of (I) as inhibitors of the glycine transporter, are provided. Definitions of Ar, R5, R6, R7, R8 and n are provided in the specification.
    Type: Application
    Filed: April 10, 2007
    Publication date: February 4, 2010
    Inventors: Clive Leslie Branch, Howard Marshall, David John Nash, Roderick Alan Porter
  • Publication number: 20090325993
    Abstract: Compounds of formula (I) or a salt thereof are provided: wherein R1, R2, R3, R4, R5, R6, R7, R9, R10, X, n, p and m are as defined in the description. Uses of the compounds as medicaments, and in the manufacture of medicament for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder are also disclosed. The invention further discloses pharmaceutical compositions and combinations comprising the compounds.
    Type: Application
    Filed: January 30, 2008
    Publication date: December 31, 2009
    Inventors: Nadia Mamoona Ahmad, Justine Yeun Quai Lai, Howard Robert Marshall, David John Nash, Roderick Alan Porter
  • Publication number: 20090326027
    Abstract: Compounds of formula (I) and salts and solvates are provided. Uses of the compounds as medicaments, and in the manufacture of medicament for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder are also disclosed. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.
    Type: Application
    Filed: March 14, 2007
    Publication date: December 31, 2009
    Inventors: Steven Coulton, Howard Robert Marshall, David John Nash, Roderick Alan Porter
  • Publication number: 20090318447
    Abstract: The invention provides a compound of formula (I) or a salt or solvate thereof: wherein R1, R2, R3, R4, R5, R6, R7, n, Het and Ar are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.
    Type: Application
    Filed: April 15, 2005
    Publication date: December 24, 2009
    Inventors: David John Nash, Roderick Alan Porter
  • Publication number: 20090270510
    Abstract: The present invention relates to compounds of formula (I), or salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.
    Type: Application
    Filed: December 21, 2005
    Publication date: October 29, 2009
    Applicant: GLAXO GROUP LIMITED
    Inventors: Daniel Marcus Bradley, Clive Leslie Branch, Wai Ngor Chan, Steven Coulton, Martin Leonard Gilpin, Andrew Jonathan Harris, Justine Yeun Quai Lai, Jacqueline Anne Macritchie, Howard Robert Marshall, David John Nash, Roderick Alan Porter, Simone Spada, Kevin Michael Thewlis, Simon Edward Ward
  • Publication number: 20090253700
    Abstract: The invention provides a compound of formula (I) or a salt or solvate thereof: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, n and Ar are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.
    Type: Application
    Filed: April 15, 2005
    Publication date: October 8, 2009
    Inventors: Clive Leslie Branch, David John Nash, Howard Marshall, Roderick Porter
  • Publication number: 20090221577
    Abstract: The invention provides a compound of formula (I) or a salt or solvate thereof: wherein R, R1, R2, R3, R4, R5, R6, R7, R8, n and Ar are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.
    Type: Application
    Filed: April 15, 2005
    Publication date: September 3, 2009
    Inventors: Clive Leslie Branch, David John Nash
  • Publication number: 20090062360
    Abstract: Compounds of formula (I) and salts and solvates thereof are provided: wherein R1 to R8 and n are defined in the description. Uses of the compounds as medicaments, and in the manufacture of medicament for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder are also disclosed. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.
    Type: Application
    Filed: March 14, 2007
    Publication date: March 5, 2009
    Inventors: Steven Coulton, Howard Robert Marshall, David John Nash, Roderick Alan Porter
  • Publication number: 20090036442
    Abstract: Disclosed are N-aroyl cyclic amine derivatives having the formula: where the variables are as define herein, and their use as pharmaceuticals, specifically as orexin receptor antagonists.
    Type: Application
    Filed: October 29, 2007
    Publication date: February 5, 2009
    Inventors: Clive Leslie BRANCH, Wai Ngor Chan, Amanda Johns, Christopher Norbert Johnson, David John Nash, Riccardo Novelli, Jean-Pierre Pilleux, Roderick Alan Porter, Rachel Elizabeth Anne Stead, Geoffrey Stemp
  • Publication number: 20090012122
    Abstract: Disclosed are N-aroyl cyclic amine derivatives having the formula: where the variables are as define herein, and their use as pharmaceuticals, specifically as orexin receptor antagonists.
    Type: Application
    Filed: October 30, 2007
    Publication date: January 8, 2009
    Inventors: Clive Leslie BRANCH, Wai Ngor Chan, Amanda Johns, Christopher Norbert Johnson, David John Nash, Riccardo Novelli, Jean-Pierre Pilleux, Roderick Alan Porter, Rachel Elizabeth, Anne Stead, Geoffrey Stemp